Charles Chan, MD, FRCPC, FCCP, FACP, University of Toronto, Toronto, ON
Joshua Wald, MD, FRCPC, McMaster University, Hamilton, ON
Moderator: Mohit Bhutani, MD, FRCPC, FCCP
Presentation of the latest evidence guiding clinical decision making for COPD therapies to optimize management of COPD patients using real-world evidence and/or case study-based examples. Debate will focus on the pro/con analysis of clinical data and case-based examples of earlier escalation of pharmacologic treatment in COPD management.
At the end of this presentation, attendees will be able to:
- Review COPD therapies in Canada, including key efficacy and safety data from clinical trial programs and/or real-world evidence studies, highlighting the various considerations needed for treatment optimization in COPD management;
- Understand how appropriate treatable traits and clinical features of disease can inform clinical decision making for COPD management and safety risk/efficacy benefit considerations when deciding on escalation of COPD treatment; and
- Discuss how patient outcome, expectations and safety considerations can affect the choice of COPD therapy for patients at varying progression of COPD disease (including mortality).
CanMEDS Roles Addressed: Collaborator, Communicator, Health Advocate, Medical Expert, Professional, Scholar
This session is co-developed by the Canadian Thoracic Society and GSK and is planned to achieve scientific integrity, objectivity and balance.